Changes in the Gut Microbiota After Hepatitis C Virus Eradication

Overview

Journal Sci Rep

Specialty Science

Date 2021 Dec 8

PMID 34876650

Citations 9

Authors

Takashi Honda

Masatoshi Ishigami

Kenta Yamamoto

Tomoaki Takeyama

Takanori Ito

Yoji Ishizu

Teiji Kuzuya

Masanao Nakamura

Hiroki Kawashima

Ryoji Miyahara

Tetsuya Ishikawa

Yoshiki Hirooka

Mitsuhiro Fujishiro

Affiliations

Soon will be listed here.

Abstract

The gut microbiota interacts with infectious diseases and affects host immunity. Liver disease is also reportedly associated with changes in the gut microbiota. To elucidate the changes in the gut microbiota before and after hepatitis C virus (HCV) eradication through direct-acting antiviral (DAA) treatment in patients with chronic hepatitis C (CHC), we investigated 42 samples from 14 patients who received DAA therapy for HCV. Fecal samples were obtained before treatment (Pre), when treatment ended (EOT), and 24 weeks after treatment ended (Post24). The target V3-4 region of the 16S rRNA gene from fecal samples was amplified using the Illumina Miseq sequencing platform. The diversity of the gut microbiota did not significantly differ between Pre, EOT, and Post24. Principal coordinates analysis showed that for each patient, the values at Pre, EOT, and Post24 were concentrated within a small area. The linear discriminant analysis of effect size showed that the relative abundances of Faecalibacterium and Bacillus increased at EOT, further increased at Post24, and were significantly increased at Post24 compared to Pre. These suggest that changes in the gut microbiota should be considered as among the various effects observed on living organisms after HCV eradication.

Citing Articles

Gut microbes associated with functional cure of chronic hepatitis B.

Honda T, Ishigami M, Ishizu Y, Imai N, Ito T, Yamamoto K Hepatol Int. 2025; .

PMID: 39869245 DOI: 10.1007/s12072-025-10776-9.

Gut Microbiota, Deranged Immunity, and Hepatocellular Carcinoma.

Scarpellini E, Scarlata G, Santori V, Scarcella M, Kobyliak N, Abenavoli L Biomedicines. 2024; 12(8).

PMID: 39200261 PMC: 11351762. DOI: 10.3390/biomedicines12081797.

Alterations in gut microbiome and metabolite profile of patients with Schistosoma japonicum infection.

Zhou C, Li J, Guo C, Zhou Z, Yang Z, Zhang Y Parasit Vectors. 2023; 16(1):346.

PMID: 37798771 PMC: 10552355. DOI: 10.1186/s13071-023-05970-3.

Molecular markers predicting the progression and prognosis of human papillomavirus-induced cervical lesions to cervical cancer.

Amin F, Naher Z, Shaik Syed Ali P J Cancer Res Clin Oncol. 2023; 149(10):8077-8086.

PMID: 37000261 DOI: 10.1007/s00432-023-04710-5.

MAIT cells and the microbiome.

Jabeen M, Hinks T Front Immunol. 2023; 14:1127588.

PMID: 36911683 PMC: 9995591. DOI: 10.3389/fimmu.2023.1127588.

References

Navas-Molina J, Peralta-Sanchez J, Gonzalez A, McMurdie P, Vazquez-Baeza Y, Xu Z . Advancing our understanding of the human microbiome using QIIME. Methods Enzymol. 2013; 531:371-444. PMC: 4517945. DOI: 10.1016/B978-0-12-407863-5.00019-8. View

Conlon M, Bird A . The impact of diet and lifestyle on gut microbiota and human health. Nutrients. 2014; 7(1):17-44. PMC: 4303825. DOI: 10.3390/nu7010017. View

Wellhoner F, Doscher N, Woelfl F, Vital M, Plumeier I, Kahl S . Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. Hepatology. 2021; 74(1):72-82. DOI: 10.1002/hep.31700. View

Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N . α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013; 58(4):1253-62. DOI: 10.1002/hep.26442. View

Naito Y, Takagi T, Inoue R, Kashiwagi S, Mizushima K, Tsuchiya S . Gut microbiota differences in elderly subjects between rural city Kyotango and urban city Kyoto: an age-gender-matched study. J Clin Biochem Nutr. 2019; 65(2):125-131. PMC: 6769410. DOI: 10.3164/jcbn.19-26. View

Toyoda H, Kumada T, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y . Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2015; 30(7):1183-9. DOI: 10.1111/jgh.12915. View

Lin R, Lee F, Lee S, Tsai Y, Lin H, Lu R . Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol. 1995; 22(2):165-72. DOI: 10.1016/0168-8278(95)80424-2. View

Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, Shinohara Y . Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab. 2012; 16(1):44-54. DOI: 10.1016/j.cmet.2012.05.012. View

Ohtani N, Kawada N . Role of the Gut-Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship. Hepatol Commun. 2019; 3(4):456-470. PMC: 6442695. DOI: 10.1002/hep4.1331. View

10.

Utzschneider D, Legat A, Fuertes Marraco S, Carrie L, Luescher I, Speiser D . T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol. 2013; 14(6):603-10. DOI: 10.1038/ni.2606. View

11.

Sartor R, Wu G . Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. Gastroenterology. 2016; 152(2):327-339.e4. PMC: 5511756. DOI: 10.1053/j.gastro.2016.10.012. View

12.

Bajaj J, Sterling R, Betrapally N, Nixon D, Fuchs M, Daita K . HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients. Aliment Pharmacol Ther. 2016; 44(6):638-43. DOI: 10.1111/apt.13732. View

13.

Ponziani F, Putignani L, Paroni Sterbini F, Petito V, Picca A, Del Chierico F . Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. Aliment Pharmacol Ther. 2018; 48(11-12):1301-1311. DOI: 10.1111/apt.15004. View

14.

Zhang Y, Lun C, Tsui S . Metagenomics: A New Way to Illustrate the Crosstalk between Infectious Diseases and Host Microbiome. Int J Mol Sci. 2015; 16(11):26263-79. PMC: 4661816. DOI: 10.3390/ijms161125957. View

15.

Perez-Matute P, Iniguez M, Villanueva-Millan M, Recio-Fernandez E, Vazquez A, Sanchez S . Short-term effects of direct-acting antiviral agents on inflammation and gut microbiota in hepatitis C-infected patients. Eur J Intern Med. 2019; 67:47-58. DOI: 10.1016/j.ejim.2019.06.005. View

16.

Ponziani F, Gasbarrini A, Pompili M . Letter to the Editor: Restructuring the Gut Microbiota of Patients with Cirrhosis After HCV Eradication: A Matter of Time?. Hepatology. 2021; 74(3):1718. DOI: 10.1002/hep.31784. View

17.

Schnabl B, Brenner D . Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014; 146(6):1513-24. PMC: 3996054. DOI: 10.1053/j.gastro.2014.01.020. View

18.

Tripathi A, Debelius J, Brenner D, Karin M, Loomba R, Schnabl B . The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018; 15(7):397-411. PMC: 6319369. DOI: 10.1038/s41575-018-0011-z. View

19.

Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran L, Gratadoux J . Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008; 105(43):16731-6. PMC: 2575488. DOI: 10.1073/pnas.0804812105. View

20.

Achiwa K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K . DSS colitis promotes tumorigenesis and fibrogenesis in a choline-deficient high-fat diet-induced NASH mouse model. Biochem Biophys Res Commun. 2015; 470(1):15-21. DOI: 10.1016/j.bbrc.2015.12.012. View